Clinical trial
Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
NCT00294866 · Fresenius Medical Care North America, Industry · Completed
Key facts
| NCT number | NCT00294866 |
|---|---|
| Title | Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients |
| Official title | An Open Label, Multi-Center Study of the Effect of Paricalcitol on Markers of Inflammation in Patients With Stage 5 Chronic Kidney Disease on Hemodialysis. |
| Lead sponsor | Fresenius Medical Care North America, Industry |
| Collaborators | Abbott Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Failure |
| Intervention type | Drug |
| Interventions | Paricalcitol |
| Enrollment | 64 |
| Start date | Mar 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Feb 22, 2006 |
| Last update posted | Apr 8, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: